SCHEMBL27247254

SCHEMBL27247254

CC1(C(=O)NCc2cc3ccc(OCc4ccncn4)cc3[nH]2)CC1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HPGDS O60760 1/20 0.38
▸ MTNR1A P48039 1/20 0.37
▸ MTNR1B P49286 1/20 0.37
▸ SYK P43405 1/20 0.35
▸ AURKB Q96GD4 1/20 0.35
▸ INCENP Q9NQS7 1/20 0.35
▸ METTL3 Q86U44 6/20 0.34
▸ METTL14 Q9HCE5 6/20 0.34
▸ NAMPT P43490 2/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ IKBKB O14920 1/20 0.32
▸ FLT3 P36888 1/20 0.32
▸ MMP13 P45452 1/20 0.32
▸ ACHE P22303 1/20 0.32
▸ MAOB P27338 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ CYP2C9 P11712 1/20 0.31
▸ MASP2 O00187 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30946202 1.00 HPGDS (0.38) HPGDSMTNR1AMTNR1BSYKAURKB
SCHEMBL30946257 0.88 MAPT (0.42) MTNR1AMTNR1BMETTL3METTL14SMN1; SMN2
SCHEMBL27248294 0.88 MAOA (0.40) MTNR1AMTNR1BMETTL3METTL14FLT3
SCHEMBL30920518 0.85 MTNR1A (0.37) MTNR1AMTNR1BMETTL3METTL14SMN1; SMN2
SCHEMBL27247644 0.85 MTNR1A (0.39) HPGDSMTNR1AMTNR1BMETTL3METTL14
SCHEMBL27247600 0.85 MTNR1A (0.40) MTNR1AMTNR1BMETTL3METTL14SMN1; SMN2
SCHEMBL27246870 0.84 MTNR1A (0.38) MTNR1AMTNR1BMETTL3METTL14SMN1; SMN2
SCHEMBL30946137 0.83 MTNR1A (0.37) MTNR1AMTNR1BMETTL3METTL14SMN1; SMN2
SCHEMBL27247567 0.83 MTNR1A (0.37) MTNR1AMTNR1BMETTL3METTL14SMN1; SMN2
SCHEMBL27247466 0.83 MTNR1A (0.37) MTNR1AMTNR1BMETTL3METTL14SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4601635-A2 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF Maze Therapeutics, Inc. (US) 2025-08-20 — — EP disclosed
US-20240199546-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF HERCULES CAPITAL, INC., AS AGENT 2024-06-20 — — US disclosed
WO-2024081748-A2 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2024-04-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199546-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF SLC6A19, SLC2A9, SLC6A3 HPGDS 4067/4885MTNR1A 158/4885MTNR1B 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback